Atlas Trials

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

Clinical trial NCT04649060 · TERMINATED

Trial details

NCT number
NCT04649060
Sponsor
Oncopeptides AB
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed Multiple MyelomaRelapsed-Refractory Multiple Myeloma
Start date
2020-12-21
Primary completion
2022-02-07
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.